Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Regan, Meredith M
Forbes, John F
Wardley, Andrew M
Price, Karen N
Gelber, Richard D
Coates, Alan S
AffiliationEuropean Institute of Oncology, Milan, Italy. email@example.com
MetadataShow full item record
AbstractAmong postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.
CitationAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. 2011, 29 (9):1117-24 J. Clin. Oncol.
JournalJournal of Clinical Oncology